Ieq Capital LLC increased its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 45.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 134,014 shares of the biotechnology company’s stock after purchasing an additional 41,620 shares during the period. Ieq Capital LLC owned approximately 0.12% of Corcept Therapeutics worth $15,442,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in CORT. BlackRock Inc. purchased a new stake in Corcept Therapeutics during the 2nd quarter valued at $1,080,964,000. First Trust Advisors LP increased its holdings in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after purchasing an additional 1,480,059 shares during the period. Bank of New York Mellon Corp purchased a new position in Corcept Therapeutics during the 2nd quarter valued at $49,185,000. Bank of America Corp DE purchased a new stake in shares of Corcept Therapeutics in the 2nd quarter worth about $28,569,000. Finally, Legal & General Group Plc bought a new position in shares of Corcept Therapeutics in the 2nd quarter worth approximately $18,962,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.
Insider Activity at Corcept Therapeutics
In other Corcept Therapeutics news, insider Joseph Lyon sold 9,190 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $116.13, for a total value of $1,067,234.70. Following the transaction, the insider owned 5,683 shares of the company’s stock, valued at approximately $659,966.79. This represents a 61.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Roberto Vieira sold 8,333 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $80.89, for a total value of $674,056.37. Following the sale, the insider owned 3,946 shares of the company’s stock, valued at approximately $319,191.94. This represents a 67.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 259,435 shares of company stock valued at $28,492,179 in the last 90 days. 20.70% of the stock is owned by company insiders.
Analysts Set New Price Targets
Several research firms have commented on CORT. Truist Financial assumed coverage on Corcept Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 target price on the stock. Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. HC Wainwright restated a “buy” rating and issued a $165.00 price target on shares of Corcept Therapeutics in a research note on Friday, September 18th. Zacks Research downgraded Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 27th. Finally, Weiss Ratings raised Corcept Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $139.50.
Get Our Latest Stock Analysis on CORT
Corcept Therapeutics Stock Down 2.2%
CORT opened at $63.56 on Friday. The stock has a market capitalization of $6.96 billion, a price-to-earnings ratio of 54.50 and a beta of 0.54. The firm has a 50 day moving average price of $99.03 and a 200-day moving average price of $77.05. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $126.38.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.17. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The company had revenue of $340.47 million for the quarter, compared to analysts’ expectations of $339.12 million. During the same quarter last year, the company posted $0.16 earnings per share. The firm’s quarterly revenue was up 64.0% on a year-over-year basis. As a group, analysts expect that Corcept Therapeutics Incorporated will post 1.97 earnings per share for the current year.
Corcept Therapeutics Profile
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Recommended Stories
- Five stocks we like better than Corcept Therapeutics
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
